Oxigene's Zybrestat reaches primary endpoint for Stage 1 of Phase II trial |
|
|
|
Published
:
Mon, 31 Dec 2007 15:17
|
BOSTON (Thomson Financial) - Oxigene Inc. said Monday that its Zybrestat drug has achieved the primary efficacy endpoint for Stage 1 of an ongoing Phase II platinum-resistant ovarian cancer clinical trial.Zybrestat is the company's therapeutic product in a class of vascular disrupting agents aimed at treating tumors by depriving them of oxygen and thereby killing the cells.The Waltham, Mass.-based biotechnology company said the clinical trial will proceed to its second stage, in which an additional 25 patients will be enrolled.Oxigene said the initial results with the Zybrestat-chemotherapy combination indicate that Zybrestat has clinical activity against a wide variety of solid tumors and support further testing and development of the drug for ovarian carcinoma.The stock closed at $2.18 on Friday.Shares rose 26% to $2.75 in premarket trading on volume of 6,700.Greg Saulniergs/pcCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1449.80 |
+51.73 (
3.63 %)
|
| SYMBOL (
2008-12-02 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
1347.00 |
+51.00 (
4.02 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
IBM
(
4:01pm ) |
|
79.84 |
+2.94 (
3.78 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
GOOGLE
(
4:00pm ) |
|
275.11 |
+9.12 (
3.37 %)
|
|
|
Print this Story
Pain Therapeutics, King Pharma's Remoxy meets Phase III primary endpoint 